 Pacira BioSciences Inc NASDAQ: PCRX has agreed to acquire Flexion Therapeutics Inc NASDAQ: FLXN for 8.50 per share in cash, plus one contingent value right CVR worth up to 8.00 per share in cash. Pacira ended Q2 of 2021 with cash, cash equivalents, and short-term investments of 646.6 million. 